Managing myelodysplastic symptoms in elderly patients

Area of Science:

• Geriatric Medicine
• Hematology
• Oncology

Background:

• Myelodysplastic syndromes (MDS) predominantly affect the elderly, with rising incidence due to population aging.
• Current risk assessment tools like the International Prognostic Scoring System inadequately address the complexities of treating elderly MDS patients, including comorbidities and age-related factors.
• Traditional management for low-risk MDS relies on supportive care, but novel agents show promise in altering disease course.

Purpose of the Study:

• To highlight the unique challenges in managing myelodysplastic syndromes (MDS) in elderly patients.
• To advocate for a personalized, integrated geriatric and oncologic approach to optimize treatment and supportive care.
• To emphasize the need for comprehensive assessment beyond traditional prognostic scores.

Main Methods:

• Review of current literature on myelodysplastic syndromes (MDS) in the elderly.
• Analysis of limitations of existing prognostic tools for this demographic.
• Discussion of novel therapeutic strategies and supportive care improvements.

Main Results:

• Elderly MDS patients present unique challenges including comorbidities, polypharmacy, and age-related functional decline, impacting treatment tolerance and outcomes.
• Novel non-conventional drugs (e.g., lenalidomide, methyltransferase inhibitors) may influence disease natural history and should complement supportive care.
• Enhanced supportive care is crucial for improving quality of life and functional performance in elderly MDS patients.

Conclusions:

• A personalized approach integrating geriatric and oncologic principles is essential for effectively managing elderly patients with myelodysplastic syndromes (MDS).
• Comprehensive assessment of functional status, comorbidities, and social support is critical for tailoring treatment and interventions.
• Early identification of deficits in daily living activities and timely interventions can significantly improve patient outcomes and support networks.